Compare Fox Corp Class B (FOX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fox Corp Class B trades at $55.56 (market cap $24.79B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Fox Corp Class B is far larger — about 3.4× Spyre Therapeutics Inc. Common Stock's market cap, and Fox Corp Class B pays a 1.04% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FOX | SYRE | |
|---|---|---|
Market Cap | $24.79B | $7.35B |
Volume | 707,876 | 1,624,631 |
Sector | Media | Health |
52-Week High | $67.76 | $108.92 |
52-Week Low | $44.39 | $22.18 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $28.16B | $6.35B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.93, down 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 beating expectations of $1.44, and fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a buy with a price target of $84.75, implying significant upside. A dividend of $0.29 per share is scheduled for payment on September 23, 2026.
The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected decline in net income margin to 9.83% in 2026 and bearish technical indicators. The stock offers value with a P/E of 14.56 and growth potential, though investors should monitor earnings consistency and market sentiment shifts.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
